SCHEMBL21753345

SCHEMBL21753345

Cc1ccc(-c2ncc(CCl)s2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 3/20 0.47
CYP11B2 P19099 2/20 0.47
LMNA P02545 4/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
RAB9A P51151 3/20 0.41
ALDH1A1 P00352 2/20 0.41
NPC1 O15118 2/20 0.41
KDM4E B2RXH2 2/20 0.41
MAPT P10636 2/20 0.41
HPGD P15428 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
TP53 P04637 1/20 0.39
TSHR P16473 1/20 0.39
NFKB1 P19838 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
GAA P10253 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
QPCT Q16769 1/20 0.35
ALOX5 P09917 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10141022 0.84 CYP11B1 (0.48) CYP11B1CYP11B2LMNASMN1; SMN2RAB9A
SCHEMBL2762765 0.84 SMN1; SMN2 (0.49) CYP11B1CYP11B2LMNASMN1; SMN2RAB9A
SCHEMBL20971215 0.83 CYP11B1 (0.38) CYP11B1CYP11B2LMNASMN1; SMN2RAB9A
SCHEMBL16603145 0.82 CYP11B1 (0.47) CYP11B1CYP11B2LMNASMN1; SMN2RAB9A
SCHEMBL6973608 0.81 CYP11B1 (0.53) CYP11B1CYP11B2LMNASMN1; SMN2RAB9A
SCHEMBL27955951 0.79 CYP11B1 (0.37) CYP11B1CYP11B2LMNASMN1; SMN2RAB9A
SCHEMBL3370403 0.78 PPARD (0.45) ALDH1A1NPC1KDM4EMAPTGAA
SCHEMBL20894503 0.76 CYP2A6 (0.45) KDM4EMAPT
SCHEMBL890214 0.75 SMN1; SMN2 (0.47) CYP11B1CYP11B2LMNASMN1; SMN2RAB9A
SCHEMBL13697899 0.75 RAB9A (0.49) CYP11B1CYP11B2LMNASMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12016852-B2 Pyrrolidine glycosidase inhibitors ASCENEURON SA (CH) 2024-06-25 US disclosed
US-20210213005-A1 PYRROLIDINE GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2021-07-15 US disclosed
WO-2020039027-A1 PYRROLIDINE GLYCOSIDASE INHIBITORS ASCENEURON S. A. (CH) 2020-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12016852-B2 Pyrrolidine glycosidase inhibitors PREP, GAA, DNPEP CYP11B1 2519/4885CYP11B2 2659/4885LMNA 1742/4885
US-20210213005-A1 PYRROLIDINE GLYCOSIDASE INHIBITORS PREP, GAA, DNPEP CYP11B1 2625/4885CYP11B2 2834/4885LMNA 1581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.